Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Frankfurt
21.11.24
08:03 Uhr
3,120 Euro
-0,240
-7,14 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
3,1003,18022:00

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MienVVeno Medical Corporation: enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium13885% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97%...
► Artikel lesen
DienVVeno Medical strebt FDA-Zulassung für VenoValve an3
DienVVeno Medical Corporation: enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval366Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November...
► Artikel lesen
ENVVENO MEDICAL Aktie jetzt für 0€ handeln
DienVVeno Medical seeks FDA approval for VenoValve2
31.10.enVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year106Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway...
► Artikel lesen
28.10.enVVeno Medical Corporation: enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe148First wave of implants successfully completed with updated delivery system performing very wellCompany on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA...
► Artikel lesen
08.10.NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges2
08.10.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,06 US-Dollar1
30.09.enVVeno Medical Corp - 8-K, Current Report2
27.09.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,4 US-Dollar1
27.09.NVNO stock touches 52-week low at $3.4 amid market challenges1
27.09.EnVVeno Medical Announces Pricing Of Public Offering3
27.09.enVVeno Medical stock falls after it prices $15M securities offering1
27.09.enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering281IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
26.09.enVVeno Medical launches public stock offering1
26.09.enVVeno Medical startet öffentliches Aktienangebot1
26.09.enVVeno Medical offers to sell common stock2
26.09.enVVeno Medical Corporation Announces Proposed Public Offering196IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
03.09.enVVeno Medical hires VP to lead VenoValve marketing2
03.09.enVVeno Medical Corporation: enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing325MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular DevicesKey Addition to Commercial Team as Company Begins Planning for the VenoValve MonetizationSeveral Upcoming...
► Artikel lesen
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1